Incyte Corporation vs VICI Properties Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while VICI Properties Inc trades at $26 (market cap $28.61B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays a 6.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VICI | |
|---|---|---|
Market Cap | $24.54B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $129.93 | $33.78 |
52-Week Low | $81.61 | $25.94 |
Enterprise Value | $20.04B | $46.16B |
Dividend Yield | — | 6.93% |
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →